한국미생물·생명공학회지 (Microbiology and Biotechnology Letters)

  • 제51권2호
  • /
  • Pages.135-146
  • /
  • 2023
  • /
  • 1598-642X(pISSN)
  • /
  • 2234-7305(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

Pathogenesis of Oncoviruses: A Systemic Review

  • Zain Ul Abedien (Institute of Microbiology, University of Agriculture Faisalabad) ;
  • Kainat Gul (Department of Microbiology, Abbottabad University of Science and Technology) ;
  • Sara Khan (Institute of Microbiology, University of Agriculture Faisalabad) ;
  • Maheen Shafiq (School of Engineering and Built Environment, Griffith University) ;
  • Khizar Rahman (Institute of Microbiology, University of Agriculture Faisalabad) ;
  • Muhammad Hassan Nawaz (Institute of Molecular Biology and Biotechnology, University of Lahore)
  • 투고 : 2023.03.09
  • 심사 : 2023.05.15
  • 발행 : 2023.06.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Viral oncology is focused on understanding the relationship between cancer and viruses, which are known to play a role in the development of certain types of cancer. Approximately 15-20% of human cancers are believed to be caused by oncogenic viruses, and as a result, there is significant interest in understanding how these viruses contribute to cancer development. There are several viruses that have been linked to cancer, including human papillomavirus, hepatitis B and C virus, Epstein-Barr virus, human T-cell lymphotropic virus type 1, Kaposi's sarcoma-associated herpesvirus, and Merkel cell polyomavirus. Each of these viruses is associated with different types of cancer, and the mechanisms by which they contribute to cancer development are diverse. This article discusses these mechanisms as well as current and future strategies for preventing and treating virus-associated cancers with the goal of presenting a thorough review of the current state of knowledge in viral oncology and to highlight the importance of continued research in this field.

키워드

과제정보

We would like to acknowledge Instamed Medical Equipment Trading LLC, UAE for their valuable support and contribution to this article.

참고문헌

  1. Krump NA, You J. 2018. Molecular mechanisms of viral oncogenesis in humans. Nat. Rev. Microbiol. 16: 684-698.  https://doi.org/10.1038/s41579-018-0064-6
  2. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. 2020. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8: e180-e190.  https://doi.org/10.1016/S2214-109X(19)30488-7
  3. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. 2015. Global burden of gastric cancer attributable to Helicobacter pylori. Int. J. Cancer 136: 487-490.  https://doi.org/10.1002/ijc.28999
  4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189: 12-19.  https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  5. Cancer statistics CDC. Available online: https://www.cdc.gov/cancer/hpv/statistics/cases.htm. Accessed Jan 24, 2023. 
  6. Fugl A, Andersen CL. 2019. Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam. Pract. 20: 62. 
  7. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1: 702-703.  https://doi.org/10.1016/S0140-6736(64)91524-7
  8. Zur Hausen H, de Villiers EM. 2014. Cancer "Causation" by infections-individual contributions and synergistic networks. Semin. Oncol. 41: 860-875.  https://doi.org/10.1053/j.seminoncol.2014.10.003
  9. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. 2009. Decreased incidence of hepatocellular carcinoma in Hepatitis B vaccinees: A 20-year follow-up study. J. Natl. Cancer Inst. 101: 1348-1355.  https://doi.org/10.1093/jnci/djp288
  10. Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. 2013. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J. Gastroenterol. 19: 8887-8894.  https://doi.org/10.3748/wjg.v19.i47.8887
  11. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. 2012. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 344: e1401. 
  12. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. 2013. Human papillomavirus and cervical cancer. Lancet 382: 889-899.  https://doi.org/10.1016/S0140-6736(13)60022-7
  13. Chang MH. 2011. Hepatitis B virus and cancer prevention. Recent Results Cancer Res. 188: 75-84.  https://doi.org/10.1007/978-3-642-10858-7_6
  14. Yasunaga JI, Matsuoka M. 2018. Oncogenic spiral by infectious pathogens: Cooperation of multiple factors in cancer development. Cancer Sci. 109: 24-32.  https://doi.org/10.1111/cas.13443
  15. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. 2016. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4: e609-e616.  https://doi.org/10.1016/S2214-109X(16)30143-7
  16. Biological agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B. pp. 1-475. (Accessed Jan. 26, 2023). 
  17. Ahmed HG, Bensumaidea SH, Alshammari FD, Alenazi FSH, ALmutlaq BA, Alturkstani MZ, et al. 2017. Prevalence of human papillomavirus subtypes 16 and 18 among Yemeni patients with cervical cancer. Asian Pac. J. Cancer Prev.18: 1543-1548. 
  18. Steben M, Duarte-Franco E. 2007. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol. Oncol. 107: S2-S5.  https://doi.org/10.1016/j.ygyno.2007.07.067
  19. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. 2007. Genetics of hepatocellular carcinoma. World J. Gastroenterol. 13: 2271-2282.  https://doi.org/10.3748/wjg.v13.i16.2271
  20. Hamdane N, Juhling F, Crouchet E, el Saghire H, Thumann C, Oudot MA, et al. 2019. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology 156: 2313-2329.e7.  https://doi.org/10.1053/j.gastro.2019.02.038
  21. Lin MV, King LY, Chung RT. 2015. Hepatitis C virus-associated cancer. Ann. Rev. Pathol. 10: 345-370.  https://doi.org/10.1146/annurev-pathol-012414-040323
  22. Goncalves PH, Ziegelbauer J, Uldrick TS, Yarchoan R. 2017. Kaposi sarcoma herpesvirus-associated cancers and related diseases. Curr. Opin. HIV AIDS 12: 47-56.  https://doi.org/10.1097/COH.0000000000000330
  23. Guasparri I, Keller SA, Cesarman E. 2004. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199: 993-1003.  https://doi.org/10.1084/jem.20031467
  24. Casper C, Corey L, Cohen JI, Damania B, Gershon AA, Kaslow DC, et al. 2022. KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine. NPJ Vaccines 7: 108. 
  25. Panfil AR, Martinez MP, Ratner L, Green PL. 2016. Human T-cell leukemia virus-associated malignancy. Curr. Opin. Virol. 20: 40-46.  https://doi.org/10.1016/j.coviro.2016.08.009
  26. DeCaprio JA. 2017. Merkel cell polyomavirus and Merkel cell carcinoma. Philos. Trans. R Soc. Lond. B Biol. Sci. 372: 20160276. 
  27. Bakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. 2020. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J. Glob. Health 10: 010405. 
  28. Bansal A, Singh MP, Rai B. 2016. Human papillomavirus-associated cancers: A growing global problem. Int. J. Appl. Basic Med. Res. 6: 84-89.  https://doi.org/10.4103/2229-516X.179027
  29. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. 2002. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21: 1510-1517.  https://doi.org/10.1038/sj.onc.1205214
  30. Ganem D, Schneider RJ. 2001. Hepadnaviridae and their replication. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, et al. 2020. Viral Hepatitis B and C Detection among Ebola Survivors and Health Care Workers in Makeni, Sierra Leone. Fields Virology. 4. 
  31. Liang TJ. 2009. Hepatitis B: the virus and disease. Hepatology 49: S13-S21.  https://doi.org/10.1002/hep.22881
  32. Gavilanes F, Gonzalez-Ros JM, Peterson DL. 1982. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins. J. Biol. Chem. 257: 7770-7777.  https://doi.org/10.1016/S0021-9258(18)34448-X
  33. Gerlich WH, Robinson WS. 1980. Hepatitis B virus contains protein attached to the 5' terminus of its complete DNA strand. Cell 21: 801-809.  https://doi.org/10.1016/0092-8674(80)90443-2
  34. Hruska JF, Clayton DA, Rubenstein JL, Robinson WS. 1977. Structure of hepatitis B Dane particle DNA before and after the Dane particle DNA polymerase reaction. J. Virol. 21: 666-672.  https://doi.org/10.1128/jvi.21.2.666-672.1977
  35. Liaw Y-F, Chu C-M. 2009. Hepatitis B virus infection. Lancet 373: 582-592.  https://doi.org/10.1016/S0140-6736(09)60207-5
  36. Nelson NP, Easterbrook PJ, McMahon BJ. 2016. Epidemiology of Hepatitis B virus infection and impact of vaccination on disease. Clin. Liver Dis. 20: 607-628.  https://doi.org/10.1016/j.cld.2016.06.006
  37. Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. 2020. Prevalence of chronic Hepatitis B virus infection in the United States. Am. J. Gastroenterol. 115: 1492-1438. 
  38. Peng CY, Chien RN, Liaw YF. 2012. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J. Hepatol. 57: 442-450.  https://doi.org/10.1016/j.jhep.2012.02.033
  39. Arbuthnot P, Kew M. 2001. Hepatitis B virus and hepatocellular carcinoma. Int. J. Exper. Pathol. 82: 77-100.  https://doi.org/10.1111/j.1365-2613.2001.iep178.x
  40. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.  https://doi.org/10.1053/j.gastro.2007.04.061
  41. Levrero M, Zucman-Rossi J. 2016. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 64: S84-S101.  https://doi.org/10.1016/j.jhep.2016.02.021
  42. Venook AP, Papandreou C, Furuse J, de Guevara LL. 2010. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15: 5-13.  https://doi.org/10.1634/theoncologist.2010-S4-05
  43. Pietschmann T, Brown RJP. 2019. Hepatitis C Virus. Trends Microbiol. 27: 379-380.  https://doi.org/10.1016/j.tim.2019.01.001
  44. Tibbs CJ. 1995. Methods of transmission of hepatitis C. J. Viral Hepat. 2: 113-119.  https://doi.org/10.1111/j.1365-2893.1995.tb00016.x
  45. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. 1998. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study. Hepatology 28: 1687-1695.  https://doi.org/10.1002/hep.510280632
  46. Khullar V, Firpi RJ. 2015. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J. Hepatol. 7: 1843-1855.  https://doi.org/10.4254/wjh.v7.i14.1843
  47. Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5: 215-229.  https://doi.org/10.1038/nri1573
  48. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.  https://doi.org/10.1016/j.cell.2011.02.013
  49. Arzumanyan A, Reis HMGPv, Feitelson MA. 2013. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 13: 123-135.  https://doi.org/10.1038/nrc3449
  50. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. 2009. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51: 581-592.  https://doi.org/10.1016/j.jhep.2009.05.022
  51. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. 2014. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol. 61: S79-S90.  https://doi.org/10.1016/j.jhep.2014.07.010
  52. Yarchoan R, Uldrick TS. 2018. HIV-associated cancers and related diseases. New Eng. J. Med. 378: 1029-1041.  https://doi.org/10.1056/NEJMra1615896
  53. Reparaz D, Aparicio B, Llopiz D, Hervas-Stubbs S, Sarobe P. 2022. Therapeutic vaccines against hepatocellular carcinoma in the immune checkpoint inhibitor era: Time for neoantigens? Int. J. Mol. Sci. 23: 2022. 
  54. Mesri EA, Cesarman E, Boshoff C. 2010. Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10: 707-719.  https://doi.org/10.1038/nrc2888
  55. Chakraborty S, Valiya Veettil M, Chandran B. 2012. Kaposi's Sarcoma associated herpesvirus entry into target cells. Front. Microbiol. 3: 6. 
  56. Sharma-Walia N, Paul AG, Bottero V, Sadagopan S, Veettil MV, Kerur N, et al. 2010. Kaposi's Sarcoma associated Herpes virus (KSHV) induced COX-2: A key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog. 6: e1000777. 
  57. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. 2013. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 8: e81355. 
  58. Oksenhendler E, Duarte M, Soulier J, Cacoub P, Welker Y, Cadranel J, et al. 1996. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 10: 61-67.  https://doi.org/10.1097/00002030-199601000-00009
  59. Lurain K, Yarchoan R, Uldrick TS. 2018. Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Hematol. Oncol. Clin. 32: 75-88.  https://doi.org/10.1016/j.hoc.2017.09.007
  60. Tagaya Y, Matsuoka M, Gallo R. 2019. 40 years of the human T-cell leukemia virus: past, present, and future. F1000Res. 8: F1000. 
  61. Matsuoka M, Jeang K-T. 2007. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 7: 270-280.  https://doi.org/10.1038/nrc2111
  62. Marino-Merlo F, Balestrieri E, Matteucci C, Mastino A, Grelli S, Macchi B. 2020. Antiretroviral therapy in HTLV-1 infection: an updated overview. Pathogens 9: 342. 
  63. Bangham CR, Miura M, Kulkarni A, Matsuoka M. 2019. Regulation of latency in the human T cell leukemia virus, HTLV-1. Ann. Rev. Virol. 6: 365-385.  https://doi.org/10.1146/annurev-virology-092818-015501
  64. Tu JJ, Maksimova V, Ratner L, Panfil AR. 2022. The past, present, and future of a human T-cell leukemia virus type 1 vaccine. Front. Microbiol. 13: 897346. 
  65. Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL. 2008. Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood 112: 3788-3797.  https://doi.org/10.1182/blood-2008-04-154286
  66. Spurgeon ME, Lambert PF. 2013. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. Virology 435: 118-130.  https://doi.org/10.1016/j.virol.2012.09.029
  67. Stakaityte G, Wood J, Knight LM, Abdul-Sada H, Adzahar NS, Nwogu N, et al. 2014. Merkel cell polyomavirus: Molecular insights into the most recently discovered human tumour virus. Cancers 6: 1267-1297.  https://doi.org/10.3390/cancers6031267
  68. DeCaprio JA. 2021. Molecular pathogenesis of Merkel cell carcinoma. Ann. Rev. Pathol. 16: 69-91.  https://doi.org/10.1146/annurev-pathmechdis-012419-032817
  69. Hesbacher S, Pfitzer L, Wiedorfer K, Angermeyer S, Borst A, Fafer-kamp S, et al. 2016. RB1 is the crucial target of the Merkel cell polyomavirus large T antigen in Merkel cell carcinoma cells. Oncotarget 7: 32956-32968.  https://doi.org/10.18632/oncotarget.8793
  70. Patel P, Modi C, McLellan B, Ohri N. 2018. Radiotherapy for inoperable Merkel cell carcinoma: a systematic review and pooled analysis. Dermatol. Pract. Concept. 8: 149. 
  71. Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD. 2016. Metastatic Merkel cell carcinoma response to nivolumab. J. Immunother. Cancer 4: 79. 
  72. Haley CT, Mui UN, Vangipuram R, Rady PL, Tyring SK. 2019. Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: papillomaviruses and Merkel cell polyomavirus. J. Am. Acad. Dermatol. 81: 1-21.  https://doi.org/10.1016/j.jaad.2018.09.062
  73. Bjornevik K, Munz C, Cohen JI, Ascherio A. 2023. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat. Rev. Neurol. 19: 160-171. 
  74. Zeng Y, Si YF, Lan GP, Wang Z, Zhou L, Tang MZ, et al. 2020. LMP2-DC vaccine elicits specific EBV-LMP2 response to effectively improve immunotherapy in patients with nasopharyngeal cancer. Biomed. Environ. Sci. 33: 849-856. 
  75. Nickles E, Dharmadhikari B, Yating L, Walsh RJ, Koh LP, Poon M, et al. 2022. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. Cancer Immunol. Immunother. 71: 1531-1543.  https://doi.org/10.1007/s00262-021-03075-3
  76. Wang X, Li J, Schowalter RM, Jiao J, Buck CB, You J. 2012. Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication. PLoS Pathog. 8: e1003021. 
  77. Prabhu SR, Wilson DF. 2016. Evidence of epstein-barr virus association with head and neck cancers: a review. J. Can. Assoc. 82: g2. 
  78. Tempera I, Lieberman PM. 2014. Epigenetic regulation of EBV persistence and oncogenesis. Semin. Cancer Biol. 26: 22-29.  https://doi.org/10.1016/j.semcancer.2014.01.003
  79. Fox RI, Luppi M, Pisa P, Kang HI. 1992. Potential role of Epstein-Barr virus in Sjogren's syndrome and rheumatoid arthritis. J. Rheumatol. Suppl. 32: 18-24. 
  80. Rickinson AB. 2014. Co-infections, inflammation and oncogenesis: Future directions for EBV research. Semin. Cancer Biol. 26: 99-115.  https://doi.org/10.1016/j.semcancer.2014.04.004
  81. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda G-A, Zhou Y, et al. 2021. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front. Public Health 8: 552028. 
  82. Narisawa-Saito M, Kiyono T. 2007. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci. 98: 1505-1511.  https://doi.org/10.1111/j.1349-7006.2007.00546.x
  83. de Freitas AC, de Oliveira THA, Barros MR, Venuti A. 2017. hrHPV E5 oncoprotein: immune evasion and related immunotherapies. J. Exper. Clin. Cancer Res. 36: 71. 
  84. Wang X, Huang X, Zhang Y. 2018. Involvement of human papillomaviruses in cervical cancer. Front. Microbiol. 9: 2896. 
  85. Howley PM. 2006. Warts, cancer and ubiquitylation: lessons from the papillomaviruses. Trans. Am. Clin. Climatol. Assoc. 117: 113-127.